Categories Health Care, Trending Stocks

Moderna’s (MRNA) stock gains on COVID-19 vaccine approval from the European Commission

The company is undergoing review for authorizations in Singapore, Switzerland and the United Kingdom

Shares of Moderna Inc. (NASDAQ: MRNA) gained 6.3% in afternoon hours on Wednesday as the company received approval from the European Commission for its COVID-19 vaccine. The stock has skyrocketed over 545% in the past one year and has gained 60% over the past three months.  


The European Commission granted a conditional marketing authorization (CMA) to Moderna’s COVID-19 vaccine based on the recommendation of the European Medicines Agency, paving the way for the rollout of vaccination programs across the European Union. The EU is the fourth region to approve Moderna’s COVID-19 vaccine. It has secured 160 million doses with the first deliveries set to begin next week.

On Monday, Moderna received authorization for its vaccine from the Ministry of Health in Israel. The MOH secured 6 million doses of the vaccine with deliveries expected to begin shortly. In December, Moderna received approval for its vaccine in the US and Canada. The company is undergoing review for authorizations in Singapore, Switzerland and the United Kingdom.

Supply update

On Monday, Moderna provided a supply update on its vaccine. The company increased its base-case global production estimate from 500 million doses to 600 million doses for 2021, and is working to build up to potentially 1 billion doses for 2021.

Moderna expects about 100 million doses to be available in the US by the end of the first quarter of 2021, with a total of 200 million doses available by the end of the second quarter. Thus far, approx. 18 million doses have been supplied to the US government. The US government has agreed to purchase 200 million doses of the vaccine with options to purchase an additional 300 million doses. The Canadian government has agreed to purchase 40 million doses.

Moderna has supply agreements with several countries to provide them with the COVID-19 vaccine. In December, the company entered into an agreement with the government of the Republic of Korea to provide 40 million doses of the vaccine, with deliveries set to begin in May 2021. Moderna is yet to receive approval for the vaccine in the country. The company has entered into agreements with Singapore and the UK as well to supply its COVID-19 vaccine.

Click here to read more on biotech stocks

Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!

Most Popular

Stock Watch: Is Darden Restaurants a good buy after earnings?

After a prolonged slowdown, the restaurant industry is returning to normal patterns but macroeconomic uncertainties and high inflation are currently playing spoilsport for it. While the pandemic-related slump forced many

Lennar (LEN) believes that despite near-term challenges, the long-term prospects for housing remain strong

Shares of Lennar Corporation (NYSE: LEN) were down 3% on Monday. The stock has dropped 36% year-to-date and 25% over the past 12 months. The homebuilder delivered mixed results for

KB Home (KBH): What did and did not work for the homebuilder in the third quarter

Shares of KB Home (NYSE: KBH) were up slightly on Friday. The stock has dropped 40% year-to-date and 35% over the past 12 months. The company delivered mixed results for

Add Comment
Viewing Highlight